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Abstract
Background: Uncontrolled blood pressure (BP) is an important modifiable risk factor for recurrent stroke. Secondary
prevention measures when implemented can reduce stroke re-occurrence by 80%. However, hypertension control
rates remain sub-optimal, and little data is available from primary care where most management occurs.
The aim of this study was to describe BP control in primary care-based patients with a previous stroke or transient
ischaemic attack (TIA) in Ireland, and to concurrently examine antihypertensive medication-dosing.
Methods: Study participants most recent office-based BP reading was compared with the NICE (NG136) and
European Society of Hypertension/ European Society of Cardiology (ESH/ESC 2013) goal of BP < 140/90 mmHg.
Optimal anti-hypertensive medication dosing was determined by benchmarking prescribed doses for each drug
with the World Health Organisation-Defined Daily Dosing (WHO-DDD) recommendations.
Results: We identified 328 patients with a previous stroke or TIA in 10 practices. Blood pressure was controlled in
almost two thirds of patients when measured against the ESH/ESC and NICE guidelines (63.1%, n = 207). Of those
with BP ≥140/90 (n = 116), just under half (n = 44, 47.3%) were adequately dosed in all anti-hypertensive
medications when compared with the WHO-DDD recommendations.
Conclusion: Blood pressure control in patients post stroke/TIA appears sub-optimal in over one third of patients. A
comparison of drug doses with WHO-DDD recommendations suggests that 47% of patients may benefit from
drug-dose improvements. Further work is required to assess how best to manage blood pressure in patients with a
previous stroke or TIA in Primary Care, as most consultations for hypertension take place in this setting.
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Introduction
Stroke has a major impact on people’s lives, with often
devastating personal, social and economic consequences
for the individual and their family. The cost of stroke in
the European Union (EU) in 2015 was estimated at €45
billion, accounting for a total mortality rate of 17%
within the EU, making it the second most common
cause of death [1]. Increased disability and mortality
rates result from recurrent strokes, yet despite this, an
assessment of the availability of secondary prevention
measures after stroke or transient ischaemic attack
(TIA) across Europe has shown significant gaps in spe-
cialist care, monitoring and treatment programmes [2].
The European Stroke Action Plan (ESAP) for the years
2018–2030 outlined targets for the development of
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stroke care [3]. The report outlined six domains in their
action plan, one of which is secondary prevention and
organised follow-up. The 5-year risk of recurrent stroke
is estimated at 9.5% with recurrent stroke often resulting
in more debilitating outcomes [4].
Management of risk factors such as smoking, hyperlip-
idaemia, obesity, diabetes, atrial fibrillation, sedentary
lifestyle, raised body mass index and hypertension, have
the potential to reduce recurrent events by up to 80% [3,
5]. Of these, researchers have demonstrated hyperten-
sion to be the most important modifiable risk factor in
stroke [6]. In recurrent stroke the risk increases by about
one-third for every 10 mmHg increase in systolic blood
pressure [7].
In a survey of secondary prevention of stroke in
Europe, satisfactory levels of blood pressure (BP) control
are achieved in less than 60% of countries [2]. Figures
from Ireland were included in this data. However, there
were limitations to this study. Authors didn’t have access
to primary registry data and many of the responses were
estimated, allowing for the possibility of unintentional
biases. A recent paper published in the Lancet showed
that Ireland, Finland and Spain have the lowest rate of
awareness, treatment and control of BP in their popula-
tions, based on an analysis of national representative
surveys in 12 high-income countries [8].
Reasons for sub-optimal BP control are multi-faceted
and include patient factors (adherence) [9, 10], physician
factors (including therapeutic inertia) [10], lifestyle issues
and treatment resistant hypertension [11]. However, a
recent study considering pseudo-resistance in high-risk
cardiovascular patients suggests that treatment resistant
hypertension may be less prevalent than expected, with
half of the patients in this study prescribed sub-optimal
doses of their anti-hypertensive medications [12].
Blood pressure guidelines for the prevention of stroke
have been the subject of much discussion with differ-
ences emerging between specialist groups. The recent
American Heart Association (AHA) guidelines have
adopted a target of < 130/80 mmHg for the secondary
prevention of stroke [13]. The European Society of Car-
diology/ European Society of Hypertension (ESC/ ESH)
changed their guidance from < 140/90 mmHg [14] to
< 130/80 mmHg in their most recent guidelines pub-
lished in 2018 [11]. Recent hypertension guidelines
from the National Institute of Health and Care Excel-
lence (NICE) have not committed to the lower target
and instead have set a target of < 140/90 mmHg for
adults under 80 years [15, 16].
The Irish health care system does not have universal
registration with a GP or mandatory coding of diseases.
Almost half of the population is registered through the
Primary Care Reimbursement Service (PCRS) and regis-
tered to one single general practitioner [17]. The
remainder are described as private patients and able to
see any general practitioner. All patients over the age of
70 years, under six, and those below defined income
levels [less than €304 (£270) gross per week for a single
person; €441 (£395) gross per week for a couple] are reg-
istered with the PCRS [18]. Of those registered with the
PCRS- three quarters receive free primary healthcare
and medications (those with the lowest income), the
remaining quarter have free access to primary care only
[19]. We based all prevalence analysis on patients who
are registered with the PCRS as we can be certain these
patients are registered with a single practice.
The primary aim of this study was to describe the
prevalence of sub-optimal blood pressure control in a
cross-sectional cohort of patients with a previous stroke/
TIA in primary care. Secondly, we wished to examine
the characteristics of this cohort- looking for associa-
tions that could predict poor blood pressure control and
thirdly we wished to assess anti-hypertensive drug dos-
ing schedules in these patients. To our knowledge, this
is the first study examining these issues in primary care.
Methods
General practices in the University of Limerick, Educa-
tion and Research Network [20] were invited to partici-
pate via email. Out of the 14 practices that responded,
ten practices were selected as they were within 2 h travel
from the university, had the capacity to host the re-
searcher and used electronic health care records. The 10
practices that participated included a variety of practice
sizes (small, medium, large) and types (urban, rural,
mixed, teaching and non-teaching) (Table 1). This was a
convenience sample but the participating practices were
purposefully selected to be representative of Irish Gen-
eral Practice [21].
Data collection was conducted in July and August
2019 according to a prespecified data extraction protocol
designed by RD (Appendix). Data collection was sup-
ported in practices by DMC, who received a summer
student research scholarship, and was supervised by RD.
This work fulfilled for the GP, the Irish Medical Council
requirement to conduct an annual audit.
Eligible patients were identified as those patients who
were coded for stroke or TIA or those who were not
coded but had a hospital diagnosed stroke or TIA in
their discharge summaries from specialists. These events
were classed as either ischaemic stroke, haemorrhagic
stroke, TIA or unknown. If patients had more than one
of these events, they were classed based on their most
severe event. Disease coding typically categorised the
type of each stroke, where this was not available or am-
biguity existed, hospital discharge summaries and con-
sultant reports were examined to clarify the diagnosis.
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All practices used electronic health care records, but
used a variety of software systems; Socrates®, Health
One™ or Helix Practice Manager. Search methods dif-
fered between the systems, some using specific diagnos-
tic searches and others disease coding, each using the
analysis function inbuilt in that system.
In Socrates®, the International Classification of
Disease-10 (ICD-10) [22] codes G45, and I60-I64 were
used, along with the International Classification of Pri-
mary Care-2 (ICPC-2) [23] specific codes K89 (Transient
cerebral ischaemia), K90 (Stroke/cerebrovascular acci-
dent), and K91 (Cerebrovascular disease) to facilitate
case identification. In Health One® and Helix Practice
Manager they searched using keywords, such as “stroke,
cerebrovascular accident, CVA, infarct, cerebral bleed,
subarachnoid haemorrhage, TIA, Transient Ischemic at-
tack” in the patient’s past history section if coding of dis-
ease was not used in that practice.
Sub-optimal BP control was assessed by comparing
the last office BP on file with the ESH/ESC 2013 [14]
and NICE guideline (NG136) [16] recommendation of
BP < 140/90 mmHg for the secondary prevention of
stroke. Only patients who were actively attending the
general practitioner were included. European guidelines
are more applicable to the Irish context and at the time
of the study Irish GPs would have been more familiar
with the 2013 ESH/ESC guideline [14] or the NICE
guidelines [24]. In the absence of an up to date Irish
guideline, the most recent published in 2010 [25], Irish
GPs are more likely to follow European and NICE guide-
lines [24] and therefore we used BP < 140/90 mmHg as
the target.
To help describe the characteristics of these patients
we recorded, if available, demographics, stroke subtype,
blood pressure, kidney function, lipid profile and drug
data. Co-morbidities of diabetes and chronic kidney dis-
ease (CKD) were also recorded. Patients were described
as having diabetes if they had ICPC codes T89 (Diabetes
insulin dependent) or T90 (Diabetes non-insulin
dependent), ICD codes E10 (Type 1 Diabetes Mellitus),
E11 (Type 2 Diabetes Mellitus), patient’s active diagnosis
contained diabetes keyword, or were taking insulin or
oral hypoglycaemic agents. Patients were described as
having CKD if an estimated Glomerular Filtration Rate
(eGFR) less than 60mls/ min/ 1.73m2 was recorded in
the last two renal function tests [26]. Anti-hypertensive
medications were recorded as defined by the British
National Formulary (BNF) 2019 [27], and included the
following drug groups: diuretics, angiotensin converting
enzyme (ACE) inhibitors, calcium channel blockers,
angiotensin II type 1 receptor blockers, adrenergic beta
antagonists and doxazosin.
The use of ambulatory blood pressure monitoring
(ABPM) was examined, especially in those with sub-
optimal BP control to identify cases of white coat hyper-
tension (a normal 24-h ABPM, with an elevated manual
office BP reading). Day time average readings > 134/84
mmHg signified sub-optimal BP control [11].
Optimal anti-hypertensive medication dosing use was
determined by benchmarking prescribed anti-
hypertensive drug doses, for each individual prescribed
drug, against the World Health Organisation-Defined
Daily Dosing (WHO-DDD) schedule. We used this as a
surrogate for investigating the adequacy of dosing. The
WHO-DDD is the assumed average maintenance dose
per day for a drug, used for its main indication in adults
[28]. Egan et al. adopted a slightly different approach,
examining the number of patients who were receiving
for each medication, diuretics apart, at least half the
maximum dose [29]. We present both approaches here.
Patients were deemed to be adequately dosed when all
prescribed drugs were at or above these thresholds.
Graphical summaries were created for all patient char-
acteristics to identify any anomalies or potential outliers.
Summary statistics were generated that were appropriate
for the explanatory variable in question (i.e. mean,
standard deviation and medians). Independent t-tests
were used to compare the mean of the various quantita-
tive variables between the groups, controlled (< 140/90
mmHg) and uncontrolled (≥140/90 mmHg) and a two-
sample comparison of proportions (chi-square test) to
similarly compare factors. Chi-squared tests were also
used to test whether a significant difference was found
between the expected frequencies in different categories
in controlled (< 140/90 mmHg) versus uncontrolled
(≥140/90 mmHg) patients. Binary logistic regression was
used to model the association between the (log) odds of
BP control (< 140/90 mmHg) and explanatory variables
of interest. All statistical analysis took place in SPSS-
version 26 [30].
Results
Ten practices participated (Table 1) with 328 patients
identified as having a previous stroke or TIA. When
Table 1 General practice characteristics
Practice Type Practice Location Practice Size Involved in post graduate GP training
Single Handed (n = 2) Urban (n = 2) < 1000 patients (n = 5) Yes (n = 3)
2–3 GPs (n = 6) Rural (n = 4) 1000–2000 patients (n = 3) No (n = 7)
> 3 GPs (n = 1) Mixed (n = 4) > 2000 patients (n = 2)
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office BP readings were compared with the ESH/ ESC
2013 [14] and NICE (NG136) [16] guidelines (< 140/90
mmHg), we found that 116 (35.9%) patients had sub-
optimal BP control.
Patient characteristics are described in Table 2. 62.2%
of the population (n = 328) studied are male with 37.8%
female. Stroke subtype included 29.3% ischaemic stroke,
9.8% haemorrhagic stroke and 41.2% TIA, with 19.8%
unknown or not recorded. 87.8% were registered with
PCRS for free GP services. Multimorbidity is a common
feature within this cohort of patients, 15.5% had
diabetes, 22.6% had CKD and 4.9% had both diabetes
and CKD.
Independent t-tests were used to compare the mean of
the various quantitative variables (age, parameters of
renal function, ambulatory blood pressure, lipids) be-
tween the two groups, controlled (< 140/90 mmHg) and
uncontrolled (≥140/90 mmHg). A two-sample compari-
son of proportions (or chi-square test) to compare fac-
tors (gender, PCRS status, co-morbidity and sub-optimal
BP control (≥140/90 mmHg) was also performed. No
statistically significant differences between the groups
were demonstrated.
Chi-squared tests were also used to test whether a
significant difference was found between the expected
frequencies and the observed frequencies in different
categories in controlled (< 140/90mmHg) versus uncon-
trolled patients (≥140/90 mmHg), and no significant
differences were observed in sex, stroke subtype, GMS
status and comorbidities. Binary logistic regression was
used to model the association between the (log) odds of
BP control and explanatory variables of interest. No pre-
dictors of sub-optimal BP were identified.
Detailed data on drug-dosing was available for 252 pa-
tients prescribed antihypertensive medications (Table 3).
For those with BP ≥140/90mmHg, 44 (47.3%) patients
and 22 (23.7%) patients were inadequately dosed, in each
of their medications, according to WHO-DDD guide-
lines [28] and Egan et al. guidelines [29] respectively. Of
the 116 patients that had uncontrolled BP ≥140/90
Table 2 Patient characteristics by blood pressure
BP < 140/90 BP≥ 140/90 no BP recorded Total % of Total
Total 207 (63.1%) 116 (35.4%) 5 (1.5%) 328 –
Female 71 (34.3%) 50 (43.1%) 3 (60%) 124 37.8%
Male 136 (65.7%) 66 (56.9%) 2 (40%) 204 62.2%
Average age (SD) 72.8 (12.3) 74 (10.5) 70.8 (8.8) 73.3 (11) –
Stroke subtype:
~ Ischaemic 57 (27.5%) 38 (32.8%) 1 (20%) 96 29.3%
~ Haemorrhagic 21 (10.2%) 10 (8.6%) 1 (20%) 32 9.8%
~ TIA 84 (40.6%) 50 (43.1%) 1 (20%) 135 41.2%
~ Unknown 45 (21.7%) 18 (15.5%) 2 (40%) 65 19.8%
GMS Status:
~ Full Medical card 152 (73.4%) 93 (80.2%) 5 (100%) 250 76.2%
~ Doctor visit card 26 (12.6%) 12 (10.3%) 0 (0%) 38 11.6%
~ Private patient 29 (14%) 11 (9.5%) 0 (0%) 40 12.2%
Multimorbidity:
~ Diabetes 32 (15.5%) 19 (16.4%) 0 (0%) 51 15.5%
~ CKD 44 (21.3%) 29 (25%) 1 (20%) 74 22.6%
~ Diabetes & CKD 13 (6.3%) 6 (5.2%) 0 (0%) 19 4.9%
~ Total Chol > 4.5 50 (17.6%)a 37 (13%)a 2 (0.7%)a 89a 31.3%a
~ LDL > 2.5 54 (19.8%)a 35 (12.8%)a 0 (0%)a 89a 32.6%a
Drugs prescribed:
~ aspirin 95 (45.9%) 64 (55.2%) 2 (40%) 161 49.1%
~ clopidogrel 37 (17.9%) 19 (16.4%) 0 (0%) 56 17.1%
~ statin 154 (74.4%) 89 (76.7%) 3 (60%) 246 75%
~warfarin 44 (21.3%) 12 (10.3%) 0 (0%) 56 17.1%
~ DOAC 14 (6.8%) 8 (6.9%) 0 (0%) 22 6.7%
ABPM ever 95 (45.9%) 64 (55.2%) 0 (0%) 159 48.5%
aTotal cholesterol and LDL assessed in a subset of patients. Total cholesterol (n = 284), LDL (n = 273)
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mmHg, 23 patients were not taking any anti-
hypertensive medication and 31 were taking a single
agent.
Results of ABPM were available for 64 (55.2%) of
the 116 patients with sub-optimal BP control. Of
those who had ABPM (n = 64), nine patients demon-
strated white coat hypertension, the remaining 55 had
sub-optimal BP control, with average day time read-
ings > 134/84 mmHg [11, 14].
Discussion
Summary of main findings
Blood pressure control was sub-optimal in approxi-
mately one-third (35.4%) of patients according to ESH/
ESC 2013 and NICE (NG136) guidelines, where BP <
140/90 mmHg is deemed satisfactory. Anti-hypertensive
medication dosing appears sub-optimal in close to half
of these patients when compared with WHO-DDD
criteria.
Comparison with existing literature
Of those identified with a previous stroke or TIA, 63.1%
had blood pressure controlled to < 140/90mmHg. This
compares well with results from a study in Norwegian
general practice finding that 47% of patients, 1 year post
stroke, had BP controlled to < 140/90 mmHg [31]. How-
ever, there is a paucity of research examining blood
pressure control and secondary prevention of stroke in
the primary care setting.
Due to an aging population, the number of people
with stroke is set to rise by 58% between 2007 and 2021
[32]. This projected rise in the number of strokes will
have a significant impact on health care spending. The
cost of stroke has been estimated at €557 million per
annum in Ireland [33], €4.11 billion (£3.6 billion) per
annum in the UK [34] and €45 billion per annum within
the EU [1]. Consequently, with rising health care costs,
it is imperative that prevention measures reducing the
incidence of stroke or further strokes, are adopted.
For clinicians, deciding which is the most appropriate
target for blood pressure control in this group of
patients is difficult. Having two or three differing guide-
lines, each recommending different targets can cause
confusion regarding the most appropriate clinical man-
agement. The United Kingdom, National Institute for
Health and Care Excellence (NICE- Clinical Guideline
NG136) [16] has recently reviewed the evidence and de-
cided that the current target of < 140/90 mmHg shall be
maintained for all adults under 80 years [16], and will
not follow the AHA guidelines to reduce blood pressure
targets to < 130/80 mmHg, as evidenced by the SPRINT
trial [35]. NICE stated that the methodology used to
measure BP in SPRINT is simply not achievable in clin-
ical care settings at this stage [36]. The current ESC/
ESH guideline [11] has changed its recommendation
from a target BP of < 140/90 mmHg [14] (as used in our
study) to < 130/80 mmHg. However, it recommends cau-
tion with lower targets, especially in those patients over
65 years where the target is 130–140/80mmHg, if toler-
ated. Caution must be exercised with all patients, as re-
ducing systolic blood pressure to < 120 mmHg may
provide benefit for some persons, but problems for
others [37].
Achieving blood pressure targets in this complex
co-morbid group of patients – with a mean age of 73
years, and in whom a quarter have CKD - can be dif-
ficult. There are occasions in practice when meeting
blood pressure guidelines is not appropriate and
higher blood pressure readings are acceptable– those
with concurrent unstable coronary artery disease,
those with previous anti-hypertensive based acute kid-
ney injury or cerebral hypo-perfusion. A further
group worth mentioning are those with extreme vari-
ability in blood pressure readings (mixed high and
low) or those with isolated systolic hypertension and
a large pulse pressure. These groups cannot often tol-
erate focused blood pressure reduction programs and
treating physicians do not pursue further after trial of
treatment, as this can impact seriously on their









0 antihypertensives prescribed: 51 (24.6%) 22 (19%) 2 (40%) 73 (22.3%)
1 antihypertensive prescribed 65 (31.4%) 31 (26.7%) 1 (20%) 97 (29.6%)
Detailed analysis of antihypertensives prescribed
Patient on ≥1 antihypertensive n = 156 n = 93 n = 3 n = 252a
Adequate dose (WHO) 73 (46.8%) 49 (52.7%) 1 (33.3%) 123 (48.8%)
Inadequate dose (WHO) 83 (53.2%) 44 (47.3%) 2 (66.6%) 129 (51.2%)
Adequate dose (Egan) 105 (67.3%) 71 (76.3%) 1 (33.3%) 177 (70.2%)
Inadequate dose (Egan) 51 (32.7%) 22 (23.7%) 2 (66.6%) 75 (29.8%)
aAntihypertensive dose not recorded for one patient
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quality of life. We accept this may be a reality for
some patients.
Interestingly, of those with uncontrolled BP ≥140/90
mmHg (n = 116), 22 patients did not have any anti-
hypertensive medications prescribed and a further 31 pa-
tients had only a single agent prescribed. Current ESC/
ESH guidelines advise that two anti-hypertensive agents
are required to ensure BP control in most instances, and
these should be commenced initially as a fixed dose
combination therapy [11].
Of the 93 patients prescribed one or more antihyper-
tensives, 47.3% (n = 44) of these did not meet the recom-
mended dose in all their anti-hypertensive drugs when
measured against the WHO-DDD guidelines (Table 3).
The WHO-DDD is a stringent measure of the adequacy
of dosing, we accept this. However to counter balance
we also analysed drug dosing from a methodology used
by Egan et al. [29]. Here, where the threshold for dosing
adequacy is much lower, almost a quarter of patients are
still inadequately dosed when BP remains > 140/90
mmHg.
It is acknowledged that a patient with a clear indica-
tion for drug treatment may sometimes not be pre-
scribed the drug due to factors like liver or kidney
failure, weight, patient receiving end of life care, and/or
previous adverse response to the drug in question. It can
be accepted that in some instances, not receiving a drug
treatment does not necessarily suggest poor medical
treatment or therapeutic nihilism. However, as Gil-
Guillen et al. suggest, physician inertia to escalate drug-
dosing in hypertension can be a significant problem up
to 70% of the time [38].
The ESC/ESH guidelines support the use of ABPM
when investigating high office blood pressure readings
[11]. It is an important tool when investigating white
coat hypertension. It also provides important informa-
tion on night time BP control which is an independent
predictor of death and negative cardiovascular outcomes
[39]. Nevertheless, providing ABPM in general practice
can be costly and is not suitable for all patients e.g. those
with pulse irregularity such as atrial fibrillation, those
who are easily confused or those who find it too uncom-
fortable to wear. Results from this study show that
ABPM could be utilised to a greater extent as just over
half the cohort have ever had ABPM. Reimbursement
for the use of ABPM by primary care practitioners in
Ireland, is available since 2018 for all PCRS registered
patients. It is anticipated that this will lead to an increase
use of ABPM as a tool for diagnosis and monitoring into
the future.
Strengths and limitations
We believe this is the first estimate of blood pressure
control in a cohort of patients post stroke/TIA in
primary care with specific consideration of anti-
hypertensive drug dosing. A further strength of this
study was that all data was collected at the level of the
patient’s file in their own general practice.
Limitations of this study include the use of 10 general
practices from the same geographical area. The cross-
sectional design took in to account BP readings from
one point in time only and did not take in to consider-
ation out of office BP monitoring or indeed the other
factors that may influence recurrent stroke (smoking,
hyperlipidaemia, obesity, diabetes, atrial fibrillation and
sedentary lifestyle). As this was a retrospective study,
there was no common protocol for the measuring and
recording of office BP. It is also accepted that the
WHO-DDD is a surrogate marker for assessing the ad-
equacy of drug-dosing.
Implications for research and practice
The results of this study have provided important infor-
mation on blood pressure control in patients who have
had a previous stroke or TIA. Recent stroke audits have
focused primarily on acute hospital care [4, 40, 41].
There is a paucity of research in primary care. Commu-
nity care and long term follow up in primary care has
been underfunded and under-resourced, despite rec-
ommendations from recent stroke audits to health au-
thorities to address this deficit [40]. Gaps in
secondary prevention could be tackled through EU-
wide policies, development of national and regional
guidelines and strategies, and direct intervention-
based reimbursement [2].
A new contract for general practice services in Ireland
has been negotiated recently [42]. This aims to provide
essential resources and funding to build the capacity for
chronic disease management in primary care. Care for
people who have had a cerebrovascular event (stroke or
TIA) is addressed as part of this plan. Providing funding
for chronic disease management is a recent advancement
in primary care in Ireland. It has been available for the
care of people with Type 2 Diabetes who are registered
with PCRS since 2017. It has benefited these patients by
improving and standardising the recording of clinical in-
formation and has also shown an improvement in the
achievement of clinical targets [43].
There is clear evidence that reducing blood pressure
to below 140/90 mmHg benefits those who have had a
previous stroke or TIA [11]. This BP level should be the
desired initial target for patients and their doctors before
considering further reductions. Further research is
needed to explore how GPs might be supported to opti-
mise the management of BP. This may involve an exam-
ination of prescriber inertia to increase anti-hypertensive
drug doses, supporting the use of out-of-office readings
to confirm sub-optimal control and enhance BP
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management, and patient strategies to encourage adher-
ence to drug therapy and the adoption of a healthy life-
style. These challenges may be met by introducing novel
approaches for BP control in primary care, such as home
care and self-care approaches [44].
Conclusion
Blood pressure control appears sub-optimal in at least
one-third of patients with a previous stroke or TIA. Half
of these patients could respond to anti-hypertensive dose
escalation. Further work is required to see how best to
manage blood pressure in patients with a previous stroke
or TIA in Primary Care, as the majority of consultations
for hypertension take place in this setting.
Appendix
Data extraction protocol
Practice No. (P1 or P2) followed by patient no. (i.e. 001–
1000-e.g. P1001, or P2001)
Gender (1 = Female 2 =Male)
GMS (0 = Private 1 = GMS 2 = DVC card)
Age in yrs.
Coded TIA (1 = yes 0 = No) ICD-10 G45, ICPC-2 K89
Coded Stroke (1 = yes 0 = No) ICD-10 I60-I64, ICPC-
2 K90–91
Coded Ischaemic stroke (1 = yes 0 = No) ICD-10 I63–
64, ICPC-2 K90–91
Coded Haemorrhagic stroke (1 = yes, 0 = no) ICD-10
I60-I62, ICPC-2 K90
Non-coded Key words (stroke, cerebrovascular acci-
dent, CVA, infarct, cerebral bleed, subarachnoid haem-
orrhage, TIA, Transient Ischemic attack
Non-coded TIA identified through chart search. Per-
sonal knowledge, medication search, cross referencing
etc. (1 = yes 0 = No)
If yes, how identified: Add free text
Non-coded STROKE identified through chart search.
Personal knowledge, medication search, cross referen-
cing etc. (1 = yes 0 = No)
If yes, how identified: Add free text
Most Recent Creatinine in mmols/L
Next most Recent Creatinine in mmols/L
Date of Most Recent Creatinine (DD/MM/YYYY)
Date of next most Recent Creatinine (DD/MM/YYYY)
Most Recent eGFR-calculate if needs be
Next most Recent eGFR-calculate if needs be
Date of Most Recent eGFR (DD/MM/YYYY)
Date next Most Recent eGFR (DD/MM/YYYY)
Most recent Total Cholesterol
Most recent LDL
Date of most recent Total Cholesterol and LDL
Date of last Recorded manual Blood Pressure if avail-
able (DD/MM/YYYY)
Systolic Blood Pressure most recent in mmHg
Diastolic Blood Pressure most recent in mmHg
Date of last Recorded 24-h ABPM if available (DD/
MM/YYYY)
Daytime average ABPM Systolic Blood Pressure in
mmHg
Daytime average ABPM Diastolic Blood Pressure in
mmHg
Nocturnal average ABPM Systolic Blood Pressure in
mmHg
Nocturnal average ABPM Diastolic Blood Pressure in
mmHg
24 h average ABPM Systolic Blood Pressure in mmHg
24 h average ABPM Diastolic Blood Pressure in
mmHg
Anti-hypertensive medication. Reference BNF 77:
March–September 2019.
Anti- hypertensive med 1 name
Anti- hypertensive med 1 dose
Anti- hypertensive med 2 name
Anti- hypertensive med 2 dose
Anti- hypertensive med 3 name
Anti- hypertensive med 3 dose
Anti- hypertensive med 4 name
Anti- hypertensive med 4 dose
Aspirin (1 = yes, 0 = no)
Plavix (yes/no)
Other anti-platelet (list name and dose)
Statin (1 = yes, 0 = no)
DOAC (1 = yes, 0 = no)
Name of DOAC
Warfarin (1 = yes, 0 = no)
Abbreviations
ABPM: Ambulatory Blood Pressure Monitoring; AHA: American Heart
Association; BP: Blood Pressure; CKD: Chronic Kidney Disease;
eGFR: Estimated Glomerular Filtration Rate; ESAP: European Stroke Action
Plan; ESC: European Society of Cardiology; ESH: European Society of
Hypertension; EU: European Union; HBPM: Home Blood Pressure Monitoring;
ICD-10: International Classification of Disease-10; ICPC-2: International
Classification of Primary Care-2; NICE: National Institute for Health and Care
Excellence; PCRS: Primary Care Reimbursement Service; TIA: Transient
Ischaemic Attack; WHO-DDD: World Health Organisation-Defined Daily
Dosing
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